This review found that treatment with renin-angiotensin system modulators had significant but modest effects on the risk of future stroke events in patients with prior strokes. The review was well conducted and the authors' conclusions are likely to be reliable.
Searching
PubMed and Cochrane Central Register of Controlled Trials (CENTRAL) were searched without language restriction to March 2011 for relevant studies; search terms were reported. The reference lists of relevant trials and recent review articles were checked for additional studies.
Study selection
Randomised controlled trials of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with a prior stroke or transient ischaemic attack were eligible for inclusion. Eligible trials were required to have a follow-up duration of at least six months and have the total patients and the number of future vascular events or recurrent stroke reported separately for the intervention and control groups. Studies that examined the efficacy of the interventions within 48 hours of an acute initial stroke, or if either of the interventions under study were used in the control groups were excluded from the review.
Some included patients presented with hypertension, cardiovascular disease and a prior stroke. The mean age of the patients ranged from 63.9 years to 76.4 years, and the time period from the initial stroke to enrolment in the trials ranged from three to 60 months. Comparisons were also made between the renin-angiotensin system modulators under study and calcium channel blockers. The primary outcomes was risk of major vascular events (a composite of death from cardiovascular causes, non-fatal stroke, and non-fatal myocardial infarction), and the risk of recurrent ischaemic or haemorrhagic stroke. Secondary outcomes were the risks of major coronary events, total deaths, deaths from cardiovascular causes and hypotension.
Two reviewers performed study selection.
Assessment of study quality
Methodological quality was assessed using the Jadad five-points scale in terms of randomisation, blinding, reporting of losses to follow-up and withdrawals.
The authors did not state how many reviewers assessed methodological quality.
Data extraction
Data were extracted to calculate relative risks for the outcomes with 95% confidence intervals for the estimates. Study authors were contacted for information on subgroups of patients with prior stroke when necessary.
Data were extracted by two independent reviewers; any discrepancies between the reviewers were resolved by a third reviewer.
Methods of synthesis
Pooled relative risks and 95% confidence intervals for the summary estimates were calculated using a Mantel-Haenszel fixed-effect model. The presence of statistical heterogeneity was assessed using Χ² and Ι², where Ι² results of less than 40% were regarded as not significant, and Ι² scores of more than 74% were indicative of significant statistical heterogeneity. Sensitivity analyses were undertaken to explore the strength of the findings and subgroup analyses were conducted to explore the effects of clinical characteristics including study population, active treatment agent, comparator agent mean age at entry and the presence of hypertension at study entry. The potential for publication bias was assessed using visual appraisals of funnel plots.
Results of the review
Eight randomised controlled trials (29,667 patients, range 194 to 20,332) were included in the review. Five studies were allocated Jadad scores of five points, one study was given a score of four points and two studies received Jadad scores of three points.
Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers was associated with statistically significant reductions of the risk of future major vascular events (RR 0.91, 95% CI 0.87 to 0.97; seven trials; Ι²=61%) and recurrent stroke (RR 0.93, 95% CI 0.86 to 0.99; eight trials; Ι²=6%). Exclusion of the smallest study from the analysis of future major vascular events continued to show a significant result indicating benefits of the intervention (RR 0.92, 95% CI 0.87 to 0.97), but statistical heterogeneity was not significant (Ι²=41%). A borderline significant benefit was also observed with renin-angiotensin system modulators compared to calcium channel blockers in reducing the risk of major vascular events (RR 0.89, 95% CI 0.80 to 1.00, three trials; Ι²=58%), but there were no differences between the interventions and calcium channel blockers for recurrent strokes.
Treatment with renin-angiotensin system modulators was associated with a statistically significant higher risk of hypotension (RR 1.87, 95% CI 1.61 to 2.17; two trials). There were no significant differences between treatment groups angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and the comparator groups in major coronary events (five trials), death from cardiovascular causes (one trial) and total death (two trials).
The results of the subgroup analyses showed similar patterns of results to the main findings for the primary outcomes of risk of major vascular events and recurrent stroke.
The results from the visual appraisals of the funnel plots showed no evidence of publication bias.
